The integral membrane protein zinc metalloprotease ZMPSTE24 possesses a completely novel structure, comprising seven long kinked transmembrane helices that encircle a voluminous 14 000 Å 3 cavity within the membrane. Functionally conserved soluble zinc metalloprotease residues are contained within this cavity. As part of an effort to understand the structural and functional relationships between ZMPSTE24 and soluble zinc metalloproteases, the inhibition of ZMPSTE24 by phosphoramidon [N-(-rhamnopyranosyl-oxyhydroxyphosphinyl)-Leu-Trp], a transition-state analog and competitive inhibitor of multiple soluble zinc metalloproteases, especially gluzincins, has been characterized functionally and structurally. The functional results, the determination of preliminary IC 50 values by the use of an intramolecular quenchedfluorescence fluorogenic peptide assay, indicate that phosphoramidon inhibits ZMPSTE24 in a manner consistent with competitive inhibition. The structural results, a 3.85 Å resolution X-ray crystal structure of a ZMPSTE24phosphoramidon complex, indicate that the overall binding mode observed between phosphoramidon and soluble gluzincins is conserved. Based on the structural data, a significantly lower potency than that observed for soluble gluzincins such as thermolysin and neprilysin is predicted. These results strongly suggest a close relationship between soluble gluzincins and the integral membrane protein zinc metalloprotease ZMPSTE24.
Introduction
Proteases are abundant, with the mammalian degradome containing approximately 2% of genome-encoded proteins (Ordó ñ ez et al., 2009) . Proteases are found in virtually every cell and tissue type, and conduct a remarkably broad range of biological functions. The human zinc metalloprotease ZMPSTE24, localized to the endoplasmic reticulum (ER) and inner nuclear membranes (Barrowman et al., 2008) , processes prelamin A, the precursor of the nuclear intermediate filament protein lamin A. Lamins comprise nuclear lamina, which provide mechanical stability to the nuclear envelope and function as scaffolds for DNA repair and replication complexes (Dittmer & Misteli, 2011) . Mutations in either ZMPSTE24 or prelamin A are associated with a spectrum of accelerated-aging diseases referred to as progerias (Worman, 2012) , and the severity of different progerias appears to be correlated with the extent of loss of ZMPSTE24 activity (Barrowman et al., 2012) . Because of its role in progerias, ZMPSTE24 has also been investigated as a biomarker for vascular aging (Ragnauth et al., 2010) . Additionally, lipodystrophy acquired from antiretroviral therapy used to treat AIDS patients is likely to result from off-target interactions of HIV (aspartyl) protease-inhibitor drugs with ZMPSTE24 ISSN 2059-7983 # 2018 International Union of Crystallography (Coffinier et al., 2007; Goulbourne & Vaux, 2010) . Historically, ZMPSTE24 has been classified as a 'CaaX protease', recognizing C-terminal tetrapeptide motifs consisting of prenylated (farnesylated or geranylgeranylated) cysteine-aliphaticaliphatic-anything and cleaving the terminal 'aaX' residues. A series of publications have suggested more general roles for ZMPSTE24 in multiple ER processes, including the proper orientation of a single-pass transmembrane -helical protein (Tipper & Harley, 2002) , the unfolded protein response, a cellular stress response of the ER (Jonikas et al., 2009) , and the removal of misfolded proteins that 'clog' the translocon during signal recognition particle (SRP)-independent protein translocation (Ast et al., 2016) . A very recent paper (Kayatekin et al., 2018) identified ZMPSTE24 as protecting against human islet amyloid polypeptide oligomer-induced proteotoxicity. A yeast ortholog of ZMPSTE24 has also been implicated in chitin biosynthesis (Meissner et al., 2010) . Moreover, a collaborative publication from our group demonstrated that substrate prenylation is dispensable for cleavage by a yeast ortholog of ZMPSTE24 (Hildebrandt et al., 2016) .
The first ZMPSTE24 family member to be discovered and characterized was a yeast ortholog which processes a-factor, an essential mating pheromone (Boyartchuk et al., 1997; Fujimura-Kamada et al., 1997) . Cloning and sequencing of the gene revealed the presence of the characteristic HEXXH 'zincin' motif of zinc metalloproteases (Hooper, 1994) ; moreover, Boyartchuk et al. (1997) commented that the protein sequence ' . . . matched a larger consensus sequence characteristic of neutral Zn metalloproteases'. X-ray crystal structures of ZMPSTE24 and a yeast ortholog (the latter determined by our group) revealed a completely novel integral membrane-protein architecture: seven transmembrane -helices enclosing a 14 000 Å 3 'reaction chamber' within the membrane interior, which contains the enzyme active-site and substrate-binding residues (Pryor et al., 2013; Quigley et al., 2013) . Analysis of these structures included comparisons with thermolysin (Pryor et al., 2013; Quigley et al., 2013) and a bacterial M48 peptidase (Quigley et al., 2013) , both of which are gluzincins: zinc metalloproteases containing the sequence HEXXH . . . E (Hooper, 1994) . We are pursuing, more deeply, an analysis of ZMPSTE24 in the context of gluzincins, with the goal of determining the extent to which this integral membrane protein zinc metalloprotease of novel structure is identical (or similar) to soluble gluzincins. In other words, fundamental 'gluzincin determinants' are encoded within the sequence and structure of ZMPSTE24, but these features are nested within an intramembrane 'reaction chamber' formed by transmembrane -helices and located within the nonpolar membrane interior. Might these novel 'non-gluzincin' features fundamentally affect the characteristics of ZMPSTE24 and significantly differentiate its behavior from soluble gluzincins? One 'benchmark' characterization of zinc metalloproteases, and gluzincins in particular, is their level of inhibition by known zinc metalloprotease inhibitors. The natural product phosphoramidon [N-(-rhamnopyranosyloxyhydroxyphosphinyl)-Leu-Trp], a peptide-like molecule secreted by Streptomyces tanashiensis and first shown to inhibit thermolysin (Suda et al., 1973) , is a transition-state analog and competitive inhibitor of multiple soluble zinc metalloproteases, particularly gluzincins (Salvesen & Narbonne, 2001) . Therefore, we considered the functional and structural characterization of the interaction of phosphoramidon with ZMPSTE24 to be an important 'foundational' determinant of the relationship between ZMPSTE24 and soluble gluzincins.
Materials and methods

Materials and reagents
The human ste24 (zmpste24) gene (HsCD00075979) was obtained from the DNASU Plasmid Repository (Arizona State University). N-Dodecyl maltoside (DDM) and C 12 E 7 were purchased from Inalco Pharmaceuticals and Anatrace, respectively. The fluorogenic peptide substrate Abz-KSKTKSVIK-Dnp was purchased as a lyophilized powder at >98% purity from Anaspec. [Abz (ortho-aminobenzoic acid) is located at the N-terminus of Abz-KSKTKSVIK-Dnp. Dnp (2,4-dinitrophenol), which is located in the modified side chain of "-Dnp-lysine at the C-terminus of Abz-KSKTKSVIK-Dnp, is a non-emitting FRET acceptor, i.e. a quencher, for Abz fluorescence.] Phosphoramidon (sodium salt) was acquired from Cayman Chemicals. All other reagents used for this study were of analytical grade.
Cloning and expression of ZMPSTE24
The zmpste24 gene was amplified by polymerase chain reaction and inserted into the yeast (Saccharomyces cerevisiae) expression vector pSGP47 using an In-Fusion HD Cloning kit (Clontech Laboratories). The pSGP47-zmpste24 plasmid contains a C-terminal rhinovirus 3C protease site and a decahistidine tag. pSGP47 uses an ADH2 promoter, inducing protein expression upon glucose depletion in the medium (Clark et al., 2010) .
Protein expression was carried out following previously published protocols with some modifications (Pryor et al., 2013) . The pSGP47-zmpste24 plasmid was transformed into S. cerevisiae strain BJ5460 (Jones, 1991; ATCC20885) by the lithium acetate-PEG method (Ito et al., 1983) . Starter cultures (120 ml) in sterile CSM-Ura medium were incubated for 18 h at 30 C with shaking at 220 rev min À1 (to an OD of $1.8-2.0). 10 ml starter culture was then transferred into a 2.8 l flask containing 1 l sterile CSM-Ura medium and the cultures were allowed to grow at 30 C for 24 h until the OD reached a value of 1.4. A total of 12 flasks of yeast were prepared for this step. After incubation, yeast cultures were spun at 3500g for 15 min. The cell pellets were pooled, resuspended in 500 ml sterile YPD medium and used to inoculate 16 l YPD medium. Additional cell growth was carried out in a fermenter for 26 h at 28 C with the addition of oxygen and agitation at 400 rev min À1 . The cells were harvested by centrifugation (3500g), flash-cooled in liquid nitrogen and stored at À80 C until use. A 16 l fermenter growth yielded $320 g of cell paste. research papers 2.3. Membrane preparation BJ5460 cells with overexpressed ZMPSTE24 ($160 g) were thawed on ice and resuspended, using a hand-held glass homogenizer, in 160 ml lysis buffer [20 mM HEPES, 50 mM NaCl, 15%(w/v) glycerol, 2 mM MgCl 2 , 2 mM -mercaptoethanol (ME), 100 mM PMSF, 2.5 mg ml À1 leupeptin, 100 U benzonase pH 7.5]. The cells were lysed by three passes at 193 MPa through a microfluidizer (MP-110 with an 87 mm interaction chamber; Microfluidics) with a pre-cooled outlet coil immersed in an ice bath. The lysate was spun at 4000g (30 min, 4 C), followed by another spin at 30 000g (30 min, 4 C) to pellet unbroken cells. The resulting supernatant from this step was spun at 205 000g (90 min, 4 C) to isolate the membrane fraction. Membranes ($25 g) were resuspended, using a hand-held glass homogenizer, in 150 ml membrane buffer (50 mM HEPES, 150 mM NaCl, 15% glycerol, 2 mM ME, 100 mM PMSF, 2.5 mg ml À1 leupeptin pH 7.5). Samples were divided into aliquots, snap-frozen in liquid nitrogen and stored at À80 C until used for purification and enzymatic assays.
Protein purification
Membrane solubilization was carried out by adding a 20%(w/v) solution of DDM to 150 ml resuspended membranes to give a final detergent concentration of 1.5%(w/v). The mixture was mixed at room temperature on a benchtop rocker, after which the mixture was spun at 4000g (20 min, 4 C) to remove any insoluble material. The solubilized membranes were incubated with 7 ml TALON cobalt metal-affinity resin (Takada) equilibrated with wash buffer [50 mM HEPES, 500 mM NaCl, 15%(w/v) glycerol, 50 mM imidazole, 2 mM ME, 100 mM PMSF pH 7.5] and 0.01%(w/v) DDM for 4 h at 4 C on a rocker. The TALON resin was then washed twice by the addition of 30 column volumes of wash buffer plus 0.01%(w/v) DDM (for each wash), followed by a low-speed centrifugation (700g, 5 min, 4 C) to separate the resin. The detergent DDM was exchanged with C 12 E 7 by rinsing the TALON resin twice with 20 column volumes of wash buffer in the presence of 0.04%(w/v) C 12 E 7 .
ZMPSTE24 was eluted with five column volumes of elution buffer [50 mM HEPES, 150 mM NaCl, 15%(w/v) glycerol, 500 mM imidazole, 0.04%(w/v) C 12 E 7 , 2 mM ME, 100 mM PMSF pH 7.5]. The fractions were pooled and concentrated to $10 ml using an Amicon spin concentrator with 50 kDa molecular-weight cutoff (50 kDa MWCO; Millipore-Sigma). The sample was loaded onto a desalting column (HiPrep 26/ 10, GE Healthcare) and eluted with desalting buffer [50 mM HEPES, 150 mM NaCl, 15%(w/v) glycerol, 0.04%(w/v) C 12 E 7 , 2 mM ME, 100 mM PMSF pH 7.5]. The ZMPSTE24containing fractions were pooled and the concentration of ZMPSTE24 was calculated by measurement of the A 280 nm using a molar extinction coefficient of 140 775 M À1 cm À1 as experimentally determined by quantitative amino-acid analysis (Molecular Structural Facility, UC-Davis Genome Center). The C-terminal polyhistidine tag was cleaved by the addition of 2.5 mg His 6 -3C protease to 10 mg ZMPSTE24. The cleavage reaction was allowed to proceed overnight (12-15 h) at 4 C. The cleavage reaction was then incubated with 2.5 ml Ni-NTA agarose resin (Qiagen) for 90 min at 4 C on a rocker. The cleaved ZMPSTE24 sample was concentrated to $2 ml using an Amicon 50 kDa MWCO spin concentrator. After an additional centrifugation (17 000g for 10 min) of the retentate, it was loaded onto a preparative size-exclusion chromatography (SEC) column (Superdex 200, 10/60 column; GE Healthcare) equilibrated with SEC buffer [20 mM HEPES, 150 mM NaCl, 5%(w/v) glycerol, 0.04%(w/v) C 12 E 7 , 2 mM ME pH 7.5]. The column was eluted with the same buffer at a flow rate of 0.7 ml min À1 . The ZMPSTE24-containing fractions were pooled, concentrated (using an Amicon 50 kDa MWCO spin concentrator) to between 8 and 10 mg ml À1 (corresponding to an approximately 30-fold reduction in volume from the original SEC fractions), snap-frozen in liquid nitrogen and stored at À80 C. A total of $3 mg of pure ZMPSTE24 was isolated from $160 g of yeast cells.
Enzyme-kinetics assay of ZMPSTE24
Steady-state enzyme kinetics of ZMPSTE24 were characterized using an intramolecular quenched-fluorescence (IQF) assay, with systematic errors arising from inner-filter and nonspecific quenching effects corrected as described in a previous methodological publication from our laboratory (Arachea & Wiener, 2017) . The fluorogenic peptide substrate Abz-KSKTKSVIK-Dnp was prepared in 2.6%(v/v) DMSO and the molar concentration was determined by measurement of the absorbance at 360 nm using a molar extinction coefficient of " = 17 530 M À1 cm À1 for "-DNP-lysine (Ramachandran & Sastry, 1962) . The enzyme reaction consisted of 0.65 mg ml À1 yeast membranes (containing overexpressed ZMPSTE24) in assay buffer (100 mM HEPES, 5 mM MgCl 2 pH 7.5) with variable peptide substrate concentrations (0-40 mM) in a total sample volume of 200 ml. After 1 min equilibration, the reaction was monitored by following the increase in fluorescence for 3 min using a M5 SpectroMax plate reader (Molecular Devices) with excitation and emission wavelengths set to 320 and 420 nm, respectively. Initial velocity (V i ) values were determined from linear fits of the corrected fluorescence versus time data, and the kinetics parameters were determined by fitting the data to Michaelis-Menten kinetics with GraphPad Prism (GraphPad Software). All measurements were performed in triplicate.
Phosphoramidon inhibition
Neat DMSO was added to dissolve a freshly opened ampoule of lyophilized phosphoramidon, and its concentration was calculated from the mass reported by the manufacturer. Aliquots of ZMPSTE24 membranes (0.65 mg ml À1 ) in assay buffer were incubated with various concentrations of phosphoramidon (0-100 mM) for 10 min in the dark, after which the enzymatic reaction was initiated by the addition of 40 or 80 mM fluorogenic peptide substrate. V i values were used to calculate the percentage activities relative to the control (i.e. enzyme reaction without phosphoramidon). IC 50 values research papers Acta Cryst. (2018). D74, 739-747
were calculated from activity (%) versus phosphoramidon concentration data using a four-parameter logistic (4PL) dose-response model (GraphPad Prism).
Crystallization of the phosphoramidon-ZMPSTE24 complex
Hanging-drop vapor diffusion was used for co-crystallization of the phosphoramidon-ZMPSTE24 complex; the method was modified from a recent crystallization report of ZMPSTE24 (Clark et al., 2017) . Prior to crystallization setups, 5.5 mg ml À1 (98.5 mM) ZMPSTE24 was incubated with 845 mM phosphoramidon (solubilized with 100% DMSO) for 1 h on ice. Protein stock solution was diluted with detergentfree buffer [20 mM HEPES, 150 mM NaCl, 5%(w/v) glycerol, 2 mM ME pH 7.5] and the ZMPSTE24-phosphoramidon solution contained 5%(v/v) DMSO. Drops were formed from 1.33 ml protein solution and 0.67 ml reservoir solution [27% PEG 3350, 170 mM ammonium sulfate, 15%(v/v) glycerol, 50 mM HEPES pH 7.5] at room temperature (23 C) and then immediately transferred to 4 C for crystal growth. Needle-like crystals of 50-400 mm in size appeared 1-3 d after setup. Crystals were harvested 21 d after setup and plunge-cooled, without additional cryoprotection, in liquid nitrogen.
X-ray data collection
Data collection was performed on GM/CA CAT 23-ID-D at the Advanced Photon Source (APS), Argonne National Laboratory using a wavelength of 1.03 Å and a beam size of 10 mm. Raster scans were used first to identify single crystals and subsequently to identify the termini of the needle-like crystals to facilitate helical data collection across the entire crystal body. Diffraction data processing was performed with the GM/CA CAT 23-ID-D automated processing pipeline using the programs XDS (for indexing and integration) (Kabsch, 2010) followed by POINTLESS (for point-group determination) and AIMLESS (for merging and scaling) (Evans & Murshudov, 2013) . Diffraction data were truncated to a maximum resolution of 3.85 Å based on a high-resolution shell CC 1/2 and I/(I) of~0.3 and 0.5, respectively (Karplus & Diederichs, 2015) .
Structure determination and refinement
Phasing of the ZMPSTE24-phosphoramidon co-crystal structure was performed via molecular replacement using Phaser (McCoy et al., 2007) from the PHENIX program suite (Adams et al., 2010) . Refinement was performed using phenix.refine (Afonine et al., 2012) , and model building and viewing utilized Coot (Emsley et al., 2010) . A sculpted, truncated search model consisting of a high-resolution ZMPSTE24 monomer (PDB entry 5syt; Clark et al., 2017) was used as a search model; portions of the N-and C-termini (Á10-15 and Á471-480), as well as external loops (Á284-292 and Á311-322) and the transmembrane helix II (Á61-99), were removed. Molecular replacement resulted in a robust solution (TFZ = 27.5) in space group P2 1 , placing two copies in the asymmetric unit. Inspection of the initial maps after a single round of rigid-body refinement revealed that transmembrane helix II could be placed in only one of the two monomers in the asymmetric unit. Outside of this distinction, both monomers of the asymmetric unit were modeled identically using twofold NCS-averaged 2mF o À F c and mF o À F c difference maps. Owing to the modest resolution (3.85 Å ) of the diffraction data, neither real-space nor xyz reciprocal-space positional refinement was performed; only individual atomic displacement parameters (ADPs) were iteratively adjusted. The final structure of the ZMPSTE24-phosphoramidon complex has been deposited in the PDB with accession code 6bh8. Data-collection and refinement statistics are given in Table 1 .
Results and discussion
Phosphoramidon inhibition of ZMPSTE24
Isolated yeast membranes containing overexpressed ZMPSTE24 were tested for susceptibility to phosphoramidon inhibition against a soluble fluorogenic ZMPSTE24 substrate, Abz-KSKTKSVIK-Dnp. This substrate is derived from a previously designed prenylated substrate, Abz-KSKTKC(farnesyl)VIK-Dnp, originally derived from K-Ras for use in characterization of the CaaX protease Rce1p (Hollander et al., 2000) and subsequently modified for increased selectivity for (hkl) is the observed intensity and hI(hkl)i is the average intensity of symmetry-related reflections. ‡ hI/(I)i is the ratio of the mean intensity to the mean standard deviation of intensity. § R work = P hkl jF obs j À jF calc j = P hkl jF obs j, where F obs and F calc are the observed and calculated structure factors, respectively. } R free was calculated using a randomly chosen 10% of the reflections. ZMPSTE24 over Rce1p (Manandhar et al., 2007) . [ We have previously used this prenylated substrate, Abz-KSKTKC(farnesyl)VIK-Dnp, extensively in studies of ZMPSTE24 and a yeast ortholog (Hildebrandt et al., 2016; Arachea & Wiener, 2017) ]. Proteolysis of this substrate obeys Michaelis-Menten kinetics, with K m and V max values of 10.0 AE 0.5 mM and 0.82 AE 0.02 nM s À1 , respectively (Fig. 1a) . Phosphoramidon displays competitive inhibition against soluble gluzincins and their respective substrates (Komiyama, Suda et al., 1975; Kenny, 1977; Rose et al., 2002) . To test whether ZMPSTE24 was susceptible to phosphoramidon inhibition and to make a preliminary assignment of its mode of inhibition, IC 50 measurements of phosphoramidon at two substrate concentrations, 40 mM (Fig. 1b) and 80 mM (Fig. 1c) , were performed, yielding values of 7.6 AE 1.1 and 10.5 AE 1.2 mM, respectively. This observed increase in IC 50 (2.9 AE 1.6 mM; P value < 0.1) with increasing substrate concentrations provides preliminary evidence consistent with competitive inhibition by phosphoramidon (Brooks et al., 2004) .
X-ray crystal structure of the phosphoramidon-ZMPSTE24 complex
Crystals of the phosphoramidon-ZMPSTE24 complex diffracted isotropically to a modest resolution (3.85 Å ). Our ability to determine an accurate structure of the complex was enabled by the use of Pearson's correlation coefficient (CC 1/2 ) to evaluate the limits of usable (nonzero information content) diffraction data (Karplus & Diederichs, 2015) . Use of CC 1/2 indicated clearly that the use of data to 3.85 Å resolution was fully warranted. [By comparison, the use of a previous 'popular' hI/(I)i < 2 cutoff would have yielded a data set to $6 Å resolution.] A feature of using this more objective and modern statistical approach to determine useful resolution is that for weakly diffracting crystals such as those of the phosphoramidon-ZMPSTE24 complex R meas can appear anomalously (or even wrongly) large in magnitude. However, CC 1/2 analysis unambiguously indicates that such high R meas values are fully compatible with low signal-to-noise data possessing nonzero information content.
Gluzincins, with the exception of the so-called 'mini-gluzincins' (Ló pez-Pelegrín et al., 2013), contain an HExxH . . . E motif centered around the zinc active-site center. The active-site residues of ZMPSTE24 are located at the base of the large, intramembrane cavern ( Fig. 2a) , where a pair of transmembrane helices provide the zinc-chelating residues (His335, His339 and Glu415) and the catalytic base (Glu336). Inspection of the active site of ZMPSTE24 revealed significant density for NCS-averaged 2mF o À F c and mF o À F c difference maps with an asymmetric molecular envelope, as expected for phosphoramidon ( Fig. 2b) . Large peaks of positive difference density indicated the position of the electron-dense indole ring and phosphoramidate moiety coordinating the Zn atom. Additionally, a region of significant electron density above the phosphoramidate/zinc center was consistent with placement of Figure 1 Inhibition of ZMPSTE24 membranes by phosphoramidon. The boxed insets display residual plots for each fit of the data to the model. (a) Activity of ZMPSTE24 against the fluorogenic peptide substrate Abz-KSKTKSVIK-Dnp. Initial velocity (V i ) data (triplicate; mean AE standard error of the mean) versus substrate concentration [S] were fitted to a Michaelis-Menten steady-state kinetics model (R 2 = 0.999). (b) Dose-response curve of phosphoramidon at 40 mM peptide substrate (R 2 = 0.992) and (c) dose-response curve of phosphoramidon at 80 mM peptide substrate (R 2 = 0.922). The increase in IC 50 as a function of substrate concentration provides preliminary evidence consistent with competitive inhibition (Brooks et al., 2004) . Competitive inhibition by phosphoramidon is observed for the gluzincins neprilysin (Kenny, 1977) and thermolysin (Komiyama, Suda et al., 1975) . the rhamnose group. The phosphoramidon molecule refines reasonably at 100% occupancy, with B factors similar to those of the surrounding protein residues and the zinc centre (100-150 Å 2 ; Fig. 2c ). The phosphoramidon tryptophan (P2 0 ) and leucine (P1 0 ) moieties bind in a canonical fashion to other structurally determined gluzincins (see below).
Relation between phosphoramidon binding to ZMPSTE24 and to soluble gluzincins
The active-site residues of all protease enzymes belong to one of two interdependent functional classes that facilitate peptide cleavage: (i) residues interfacing with peptide backbone atoms and/or promoting cleavage of the scissile bond (i.e. catalytic residues) or (ii) residues responsible for recognizing specific peptide side-chain identities or chemical properties (i.e. specificity-pocket residues). Each element of the active-site structure works in concert to position the appropriate scissile peptide bond, which in the case of zinc metalloproteases is in proximity to the zinc center (Schechter & Berger, 1967 , 1968 . While the natural product inhibitor phosphoramidon exploits both of these functional classes of active-site protease residues, it primarily targets specificity pockets that are present in gluzincins, as manifested by the ability of phosphoramidon to inhibit both thermolysin and neprilysin (Suda et al., 1973; Rose et al., 2002) . However, the extent to which catalytic and specificity-pocket residues of gluzincins are maintained within the cavernous reaction cavity of the integral membrane protein gluzincin ZMPSTE24 had yet to be investigated, in detail, prior to this present study.
Comparison of the structure of ZMPSTE24 complexed with phosphoramidon with the known structures of the phosphoramidon-thermolysin (Tronrud et al., 1986) and phosphoramidon-neprilysin (Oefner et al., 2000) complexes reveals conservation of both the catalytic and specificitypocket regions (Fig. 3) . Catalytic residues 'sandwiching' the phosphoramidon molecule are generally conserved among the three gluzincins (Figs. 3a, 3b and 3c) including, using ZMPSTE24 numbering, the -strand-derived Asn265 side-chain amide and Ala266 main-chain carbonyl as well as an opposing -helical element providing the His459 and Arg465 side chains. The notable exception is the presence of a tyrosine residue (Tyr157; Fig. 3b ) in thermolysin that forms an extra hydrogen-bond interaction with the rhamnose ring of phosphoramidon. The specificity pockets of gluzincins are positioned to bind residues immediately C-terminal to the scissile bond (S1 0 ) and C-terminally distal to the scissile bond (S2 0 ) (Figs. 3d, 3e and 3f The phosphoramidon-binding specificity pocket of ZMPSTE24 compared with those of the gluzincins thermolysin and neprilysin. The left-hand panel illustrates the residues beyond the conserved HExxH . . . E motif that form hydrogen-bond contacts with phosphoramidon in (a) ZMPSTE24 (PDB entry 6bh8; this work), (b) thermolysin (PDB entry 1tlp; Tronrud et al., 1986) and (c) neprilysin (PDB entry 1dmt; Oefner et al., 2000) . The right-hand panel indicates the residues responsible for forming the specificity pockets for residues immediately C-terminal to the scissile bond (S1 0 ) and C-terminally distal to the scissile bond (S2 0 ) as present in (d) ZMPSTE24, (e) thermolysin and ( f ) neprilysin. Note that the specificity pockets lie below the plane of the zinc center and catalytic residues depicted in (a), (b) and (c). phosphoramidon (Fig. 2c ). In addition to their conserved consensus motif and zinc-ligation scheme, gluzincins share a preference for aliphatic or aromatic residues at the substrate (P1 0 ): a structural motif exploited by phosphoramidon, resulting in its enhanced affinity towards gluzincins Salvesen & Narbonne, 2001) . Indeed, comparison of the S1 0 specificity pocket of ZMPSTE24 with those of thermolysin and neprilysin reveals a similar hydrophobic pocket, with the exception of the aromatic phenylalanine that is present in thermolysin (Phe130) and neprilysin (Phe106) but is substituted by a leucine (Leu438) in ZMPSTE24. The indole ring of the P2 0 tryptophan in phosphoramidon makes limited nonbonded contacts with the S2 0 specificity pockets compared with the extensive additional interactions of neprilysin with a pair of arginine residues (Arg118 and Arg102; Fig. 3f ). Overall, the differential constitution of the ZMPSTE24 specificity pocket, as opposed to those of thermolysin and neprilysin, suggests that the potency of phosphoramidon is significantly diminished in ZMPSTE24 compared with thermolysin and neprilysin.
Conclusions
Functional and structural characterization of the interaction of the zinc metalloprotease natural product peptidic inhibitor phosphoramidon with ZMPSTE24 indicates that its mechanism of action on this integral membrane protein zinc metalloprotease is likely to be similar to its action upon soluble gluzincins (i.e. competitive inhibition), but needs to be confirmed by more rigorous and comprehensive titrations of phosphoramidon against a larger subset of the substrate concentrations used in our steady-state kinetic assays. The structural binding mode of phosphoramidon to ZMPSTE24 is similar to that observed in soluble gluzincins, but we predict lessened potency. This prediction can be rationalized by an observation of less extensive interactions of the inhibitor with the S1 0 and S2 0 specificity pockets of ZMPSTE24 compared with the soluble gluzincins. Therefore, despite the provocatively novel structural aspects of ZMPSTE24, namely the presence of a 14 000 Å 3 intramembranous reaction cavity in which the active site is sequestered away from bulk solvent, ZMPSTE24 shares significant structural and functional properties with soluble gluzincins.
